Zhong Guo Jing Ji Wang·2026-01-13 08:43Core Viewpoint - Dize Pharmaceutical (688192.SH) has announced a projected net loss for the year 2025, despite an expected significant increase in revenue compared to the previous year. Financial Performance - The company anticipates a revenue of approximately 800 million yuan for 2025, which represents an increase of about 440.1 million yuan or 122.28% year-on-year [1] - The projected net loss attributable to shareholders is around 770 million yuan, a reduction of approximately 75.96 million yuan or 8.98% compared to the previous year [1] - The expected net loss after deducting non-recurring gains and losses is about 850 million yuan, which is a decrease of around 48.89 million yuan or 5.44% year-on-year [1] Historical Financial Data - From 2019 to 2024, the company's revenue figures were 41.02 million yuan, 27.76 million yuan, 10.29 million yuan, 0 yuan, 91.29 million yuan, and 360 million yuan respectively [2] - The net profit attributable to shareholders during the same period was -446 million yuan, -587 million yuan, -670 million yuan, -736 million yuan, -1.108 billion yuan, and -846 million yuan [2] - The net profit after deducting non-recurring gains and losses was -449 million yuan, -393 million yuan, -682 million yuan, -785 million yuan, -1.161 billion yuan, and -899 million yuan [2] - The net cash flow from operating activities was -366 million yuan, -410 million yuan, -492 million yuan, -603 million yuan, -968 million yuan, and -651 million yuan [2] Fundraising Activities - Dize Pharmaceutical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on December 10, 2021, issuing 40.01 million shares at a price of 52.58 yuan per share [3] - The total amount raised from the initial public offering was 2.103 billion yuan, with a net amount of 1.987 billion yuan after deducting issuance costs [3] - The company raised a total of 3.899 billion yuan from two fundraising activities [5]